immunocompetent donor cells; (2) a host antigen not shared by the donor; (3) mild or absent host-versus-graft immune response. The ways in which the third condition may be fulfilled other than that described above are immaturity of the host's immune system at the time of grafting, natural immune deficiency of the host Or immunosuppression of the host by tumour, drugs or irradiation.
' The effector cells of GVHD in the rat were shown to be present among the small recirculating lymphocytes collected from the thoracic duct. Further evidence of T cell involvement in GVHR was the demonstration that in the chicken this Condition could be produced by lymphocytes I Report of meeting of Section of Clinical Immunology & Anergy, 9 March 1981 . Accepted 21 July 1981 0141-0768/81/110849-03/$01.00/0 taken from bursectomized but not from thymectomized donors. Current interest is directed at the role in GVHR and GVHD of the various subsets of these. T lymphocytes. Two donor-derived T cell subsets identified in the enlarged spleens of mice undergoing GVHR, are the proliferative T-helper (Th) and the T-cytotoxic (Tc) cells. These donor lymphocytes have been found to bear host-derived H-2 antigens on their surfaces. Each subset bears the antigen to which it reacts; Ia antigens in the case of Th and K and D antigens in the case of Tc. It would seem reasonable that the proliferating T helper cells bring about the enlargement of lymphoid tissue and that the cytotoxic cells cause the atrophic and degenerative changes seen in GVHD. However, the experiments reviewed by Klein (1978) suggest that it is the T-helper subset which plays the dominant role both in the generation of the disease and in lymphoid enlargement. This conclusion arises from a comparison of the severity ofGVHD which resulted when there were small or large molecular differences between host and donor H-2K and H-2D antigens. Mutation was responsible for the smaller antigenic differences, recombination for the larger. Surprisingly, the smaller molecular differences between host and donor provoked the more rapidly lethal GVHD. Parallel in vitro studies showed that the mixed lymphocyte proliferative reaction (a T helper function) was also stronger when the antigenic differences were small, whereas cell-mediated Iympholysis (a Tc function) showed no marked dependence on the type of K or D antigen difference.
Animal studies offer a number of strategies to avoid GVHR. Immature but potentially immunocompetent cells in a graft of embryonic spleen should acquire tolerance to host antigens. They should also develop normal reactivity to antigens they encounter when they mature. Recently, pretreatment of graft cells with strong antisera against thymocytes has been shown to eliminate mature T cells and some but not all of their precursors. Such grafts partially or wholly repopulate the haemopoietic systems of irradiated recipients and enable them to mount effective if not always totally normal immune responses, without causing GVHD.
Dr D W Mason of the MRC Immunology Unit, Sir William Dunn School of Pathology, Oxford, reported on the use of monoclonal antisera to identify the T cell subsets which participate in GVHR. Two such antisera separated two distinct functional populations of T cells in the rat: one f) 1981 The Royal Society of Medicine consisted of helper (Th) cel1s, the other showed both T suppressor and T cytotoxic-precursor activities (Ts/Tc). Lymphocytes obtained from the thoracic ducts of rats were segregated either by using the fluorescence activated cel1 sorter to separate cel1s label1ed by fluorescein-conjugated monoclonal antibody against one of the subsets, or by centrifugal separation of those cel1s which form rosettes with red blood cel1s coated with monoclonal antibody. Lethal GVHD results when thoracic duct lymphocytes from a parental strain are injected into a sublethal1y irradiated F 1 hybrid recipient. A similar GVHD results when the donor lymphocyte population is depleted of either the Th or the Ts/Tc subset, but not if both subsets are removed. Therefore either subset can cause GVHD. The mechanisms, however, may be different in the two cases. Animals injected with the Ts/Tc subset showed signs of immunosuppression which might mediate the GVHD. Experimental1y, recipients of Ts/Tc cel1s at a dose which causes GVHD show a depressed host antibody response to DNP. The antibody response was distinguished as host rather than donor by means of host-specific IgG light chains. It was suggested that the Th-mediated GVHD depends on stimulation of the donor cel1s by Ia antigens present on host dendritic cells. This leads to production of Iymphokines by the donor Th cel1s and damage consequent upon activation of host macrophages. Support for this was found in a preliminary experiment in which F I hybrid hosts showed attenuation of the GVHD if they had been repopulated with donor strain dendritic cells (among other haemopoietic cells) prior to chal1enge with donor Th cel1s.
This suggested role for the dendritic Langerhans cell was also discussed by Professor Humphrey in his summary. Circumstantial evidence derives from the observation that the principal sites of GVHD in man (skin, gut, liver and lymphoid tissues) are particularly rich in these cells. In addition, he reported that donor lymphocytes obtained from GVHD patients do not respond to challenge with recipient lymphocytes, major candidates for the role of stimulator host cells.
The role of the host's lymphocytes in experimental GVHR was considered next by Professor W L Ford (of the University of Manchester). There is a 30-fold enlargement of the popliteal lymph node of the F I hybrid rat when T lymphocytes from one of the parental strains are injected into its footpad. Most of this increase is attributable to the proliferation of host lymphocytes with a bias towards B .lymphocyte activation. The stimulus to the activation of host cells is unknown, although the operation of nonspecific mitogenic factors has been suggested.
Professor
Ford discussed the major histocompatibility complex (MHC) and the host cell response. Induction of this response might require that host and donor (a) share MHC allotypes, (b) carry different MHC allotypes, (c) carry some shared and some different MHC allotypes, as is the case with the parental to F 1 hybrid reaction.
Congenital1y athymic (nude) rats are completely unable to reject skin allografts and ought to be ideal hosts for GVH reactions. Rolstad & Fossum (1981) found that they give a very diminished popliteal lymph node reaction as hosts to allogeneic cel1s. Subsequently, it was found that nude rats, heterozygous at the MHC, only give substantial GVHR when the donor and host share an MHC haplotype. A similar situation prevails in thymectomized irradiated recipients, where T cells cause poor reactions in completely MHC allogeneic hosts but cause larger reactions in the F I hybrid. The likely explanations are that MHC sharing is a necessity for host cell activation by the donor cells, or that the alloreactive donor T cells are eliminated by an alloantibody which they have somehow induced the host's B cells to produce; this is the 'suicidal collaboration' of Piquet & Vassali (1980) . Subsequent experiments have more closely defined the MHC requirements for host cell activation. A popliteal lymph node reaction was induced with donor T cells. Then parental strain B cells, either syngeneic with or allogeneic to the donor cells, were injected intravenously. The B cells were marked with a light chain allotype so that their proliferation in the reaction could be assessed. So far the results have indicated that parental strain B lymphocytes which are allogeneic to the donor cells proliferated vigorously in the popliteal lymph node. In another experiment, the serum of nude recipients of allogeneic T cells was titrated for alloantibody. . Moderate titres of anti-donor antibody were found at four days after the intravenous injection of donor cel1s. This suggests the MHC sharing may not be a requirement of host cel1 activation by alloreactive donor cells; 'suicidal collaboration' mediated by a non-MHC-restricted helper mechanism is adequate explanation for the poor response in nude rat hosts. Differences between GVHD in man and in experimental animal models were reiterated by Dr E C Gordon Smith of the Royal Postgraduate Medical School, London. In man, bone marrow transplants were given only to those with severely abnormal haemopoietic and/or immune systems. Clinically, the main effects of GVHD are on the liver, skin, gut and lymphoid tissue. The disease was either of the acute type, appearing within a few weeks after grafting, or of a more chronic type. Chronic disease may be preceded by the acute form. The organ involved tends to vary, as does the severity and the duration of GVHD in man. Human GVHD patients tend to be followed up for longer periods than do experimental animals. This has allowed the fortuitous clinical observation of the effects of viral infection to be made. A number of instances have been reported of onset of chronic GVHD following infection with chicken pox or measles virus, with a skin distribution following that of the viral lesions. Viral intervention may also account for the occasional GVHD in patients grafted with syngeneic or even autologous bone marrow.
It is not necessary to fully match the donor and recipient at the MHC locus to avoid GVHD. Cyclosporin A, a fungal metabolite, appears to reduce the severity though not the incidence of GVHD. This, and perhaps antilymphocyte globulin (ALG), may suppress manifest GVHD. The idea arising from recent animal experiments of removing all of the reactive cells, e.g. by treatment of the bone marrow cells with ALG prior to grafting, has not yet been applied successfully in man. It is possible that GVHD has some beneficial effects, for leukemic patients given allogeneic bone marrow grafts had less frequent leukemic relapses than did patients given syngeneic bone marrow.
Professor Humphrey, as a convert from the mouse, summarized the difficulties of applying wisdom gained from animal studies to the human disease. Particular problems were the logistic ones of experiments involving patients. Furthermore, neither the graft nor the recipient in man were strictly comparable to their equivalents in experimental animal models of GVHD.
Grafts matched for all MHC antigens in man still cause GVHD, presumably by reacting to minor histocompatibility antigens (HA). The question arises as to whether GVHD against such minor HA requires a degree of MHC compatibility between the stimulator and responder cells. Evidence that MHC compatibility is required, for atleast the stimulation of GVHD effector T cells, comes from the work of Korngold & Sprent (1980) . They studied the ability of lymph node cells from CBA donors to cause GVHD in RIO.BR hosts (congenic at the H-2 locus but differing at 6 minor HA loci In human bone marrow recipients, potential minor HA such as Lewis antigens in secretors or Ig allotypes expressed by host lymphocytes may have a similar requirement for MHC matching before they can cause GVHD. This conclusion suggests that some forms of GVHR may require close MHC matching and that grafts between relatives syngeneic or partially allogeneic at this locus may carry their own inherent problems.
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